Established and emerging variants of glioblastoma multiforme: Review of morphological and molecular features

Folia Neuropathologica

Volumn 50, Issue 4, 2012, Pages 301-321

  Karsy, Michael ^a   Gelbman, Marshall ^a   Shah, Paarth ^a   Balumbu, Odessa ^a   Moy, Fred ^a   Arslan, Erol ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Department of Orthopaedics and Traumatology   (Turkey)

Author keywords

Astrocytoma; Brain tumours; GBM; Glioblastoma multiforme; Glioma; Variant; WHO

Indexed keywords

ALPHA 1 ANTITRYPSIN; B RAF KINASE; CHYMOTRYPSIN A; COLLAGEN TYPE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; GELATINASE A; GELATINASE B; ISOCITRATE DEHYDROGENASE 1; LAMININ; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROTEIN KINASE B; PROTEIN P53; PROTEIN S 100; RETICULIN; STEM CELL FACTOR; UVOMORULIN; VIMENTIN;

ASTROCYTOMA; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME LOSS; CLINICAL FEATURE; EPITHELIZATION; GENE AMPLIFICATION; GENE MUTATION; GENETIC VARIABILITY; GIANT CELL TUMOR; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HISTOPATHOLOGY; HUMAN; MOLECULAR PATHOLOGY; MORPHOLOGICAL TRAIT; NEUROECTODERM TUMOR; NONHUMAN; OLIGODENDROGLIOMA; PONTINE GLIOMA; PREVALENCE; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION;

EID: 84873397441     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: 10.5114/fn.2012.32361     Document Type: Review

References (173)

1. Actor B, Cobbers JMJL, Büschges R, Wolter M, Knobbe CB, Lichter P, Reifenberger G, Weber RG. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosom Cancer 2002; 34: 416-427.
2. Alatakis S, Stuckey S, Siu K, McLean C. Gliosarcoma with osteosar-comatous differentiation: review of radiological and pathological features. J Clin Neurosci 2004; 11: 650-656.
3. Albuquerque L, Pimentel J, Costa A, Cristina L. Cerebral granular cell tumors: report of a case and a note on their nature and expected behavior. Acta Neuropathol 1992; 84: 680-685.
4. Asai A, Miyagi Y, Sugiyama A, Gamanuma M, Hong SH, Takamo-to S, Nomura K, Matsutani M, Takakura K, Kuchino Y. Negative effects of wild-type p53 and s-Myc on cellular growth and tumo-rigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J Neurooncol 1994; 19: 259-268.
5. Avninder S, Sharma MC, Deb P, Mehta VS, Karak AK, Mahapatra AK, Sarkar C. Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations - a study of 32 cases. J Neurooncol 2006; 78: 123-127.
6. Bailey P, Cushing H. A Classification of the Tumors of the Glioma Group on a Histogenetic Basis With a Correlated Study of Prognosis. JB Lippincott Co., Philadelphia 1926.
7. Banerjee AK, Sharma BS, Kak VK, Ghatak NR. Gliosarcoma with cartilage formation. Cancer 1989; 63: 518-523.
8. Barresi V, Cerasoli S, Morigi F, Cremonini AM, Volpini M, Tuccari G. Gliosarcoma with features of osteoblastic osteosarcoma: a review. Arch Pathol Lab Med 2006; 130: 1208-1211.
9. Barth RF, Kaur B. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol 2009; 94: 299-312.
10. Barut F, Kandemir NO, Ozdamar SO, Gul S, Bektas S, Gun BD, Bahadir B. Gliosarcoma with chondroblastic osteosarcomatous differentation: report of two case with clinicopathologic and im munohistochemical features. Turk Neurosurg 2009; 19: 417-422.
11. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF, Villani R, Cheresh DA, Black PM. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 2001; 49: 380-389, discussion 390.
12. Biernat W, Aguzzi A, Sure U, Grant JW, Kleihues P, Hegi ME. Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells. J Neuropathol Exp Neurol 1995; 54: 651-656.
13. Birner P, Toumangelova-Uzeir K, Natchev S, Guentchev M. Ex pression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression. Folia Neuropathol 2011; 49: 88-93.
14. Boerman RH, Anderl K, Herath J, Borell T, Johnson N, Schaeffer-Klein J, Kirchhof A, Raap AK, Scheithauer BW, Jenkins RB. The glial and mesenchymal elements of gliosarcomas share similar genetic alterations. J Neuropathol Exp Neurol 1996; 55: 973-981.
15. Bonavia R, Inda MDM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011; 71: 4055-4060.
16. Brat DJ, Scheithauer BW, Medina-Flores R, Rosenblum MK, Burger PC. Infiltrative astrocytomas with granular cell features (granular cell astrocytomas): a study of histopathologic features, grading, and outcome. Am J Surg Pathol 2002; 26: 750-757.
17. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 2009; 4: e7752.
18. Brooks WH, Markesbery WR, Gupta GD, Roszman TL. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 1978; 4: 219-224.
19. Burger PC, Pearl DK, Aldape K, Yates AJ, Scheithauer BW, Passe SM, Jenkins RB, James CD. Small cell architecture - a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 2001; 60: 1099-1104.
20. Burger PC, Scheithauer BW, Vogel FS. The Brain: Tumors. In: Burger PC, BW Scheithauer, FS Vogel (eds.). Surgical Pathology of the Nervous System and its Coverings. Churchill Livingstone, New York 2002.
21. Burger PC, Vollmer RT. Histologic factors of prognostic significance in the glioblastoma multiforme. Cancer 1980; 46: 1179-1186.
22. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
23. Carstens PH, Johnson GS, Jelsma L F. Spinal gliosarcoma: a light, immunohistochemical and ultrastructural study. Ann Clin Lab Sci 1995; 25: 241-246.
24. Castellano-Sanchez AA, Ohgaki H, Yokoo H, Scheithauer BW, Burger PC, Hamilton RL, Finkelstein SD, Brat DJ. Granular cell astrocytomas show a high frequency of allelic loss but are not a genetically defined subset. Brain Pathol 2003; 13: 185-194.
25. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008. Source: Central Brain Tumor Registry of the United States, Hinsdale, IL 2012; website: www.cbtrus.org
26. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, Loeffler JS. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004; 22: 1926-1933.
27. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, Vanden Berg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M, Phillips HS. A hierarchy of self-renewing tumorinitiating cell types in glioblastoma. Cancer Cell 2010; 17: 362-375.
28. Chimelli L, Symon L, Scaravilli F. Granular cell tumor of the fifth cranial nerve: further evidence for Schwann cell origin. J Neuro pathol Exp Neurol 1984; 43: 634-642.
29. Chorny JA, Evans LC, Kleinschmidt-DeMasters BK. Cerebral granular cell astrocytomas: a Mib-1, bcl-2, and telomerase study. Clin Neuropathol 2000; 19: 170-179.
30. Colman H, Aldape K. Molecular predictors in glioblastoma: to ward personalized therapy. Arch Neurol 2008; 65: 877-883.
31. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 1988; 62: 2152-2165.
32. de Carvalho AC, Nelson K, Lemke N, Lehman NL, Arbab AS, Kalkanis S, Mikkelsen T. Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells 2010; 28: 181-190.
33. Donev K, Scheithauer BW, Rodriguez FJ, Jenkins S. Expression of diagnostic neuronal markers and outcome in glioblastoma. Neuropathol Appl Neurobiol 2010; 36: 411-421.
34. Faury D, Nantel A, Dunn SE, Guiot M-C, Haque T, Hauser P, Garami M, Bognar L, Hanzely Z, Liberski PP, Lopez-Aguilar E, Valera ET, Tone LG, Carret AS, Del Maestro RF, Gleave M, Montes JL, Pietsch T, Albrecht S, Jabado N. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows in - creased YB-1 expression in tumors. J Clin Oncol 2007; 25: 1196-1208.
35. Feigin I, Allen LB, Lipkin L, Gross SW. The endothelial hyperplasia of the cerebral blood vessels with brain tumors, and its sarcomatous transformation. Cancer 1959; 11: 264-277.
36. Figarella-Branger D, Maues de Paula A, Colin C, Bouvier C. Histo - molecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. Rev Neurol (Paris) 2011; 167: 683-690.
37. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60: 1383-1387.
38. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocc o R, Foroni C, Dimeco F, Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-7021.
39. Geddes JF, Thom M, Robinson SF, Révész T. Granular cell change in astrocytic tumors. Am J Surg Pathol 1996; 20: 55-63.
40. Geranmayeh F, Scheithauer BW, Spitzer C, Meyer FB, Svensson-Engwall A-C, Graeber MB. Microglia in gemistocytic astrocytomas. Neurosurgery 2007; 60: 159-66; discussion 166.
41. Ghods AJ, Irvin D, Liu G, Yuan X, Abdulkadir IR, Tunici P, Konda B, Wachsmann-Hogiu S, Black KL, Yu JS. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 2007; 25: 1645-1653.
42. Giangaspero F, Cenacchi G. Oncocytic and granular cell neoplasms of the central nervous system and pituitary gland. Semin Diagn Pathol 1999; 16: 91-97.
43. Grant JW, Steart PV, Aguzzi A, Jones DB, Gallagher PJ. Gliosarcoma: an immunohistochemical study. Acta Neuropathol 1989; 79: 305-309.
44. Gravendeel LAM, Kouwenhoven MCM, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, De Moor B, Eilers PH, van der Spek PJ, Kros JM, Sillevis Smitt PA, van den Bent MJ, French PJ. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009; 69: 9065-9072.
45. Han SJ, Yang I, Ahn BJ, Otero JJ, Tihan T, McDermott MW, Berger MS, Prados MD, Parsa AT. Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients. Cancer 2010; 116: 1358-1366.
46. Han SJ, Yang I, Otero JJ, Ahn BJ, Tihan T, McDermott MW, Berger MS, Chang SM, Parsa AT. Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients. J Neurosurg 2010; 112: 990-996.
47. Han SJ, Yang I, Tihan T, Chang SM, Parsa AT. Secondary gliosarcoma: a review of clinical features and pathological diagnosis. J Neurosurg 2010; 112: 26-32.
48. Han SJ, Yang I, Tihan T, Prados MD, Parsa AT. Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol 2010; 96: 313-320.
49. Harada K, Nishizaki T, Ozaki S, Kubota H, Ito H, Sasaki K. Intratumoral cytogenetic heterogeneity detected by comparative ge nomic hybridization and laser scanning cytometry in human gliomas. Cancer Res 1998; 58: 4694-4700.
50. Harris CP, Townsend JJ, Brockmeyer DL, Heilbrun M P. Cerebral granular cell tumor occurring with glioblastoma multiforme: case report. Surg Neurol 1991; 36: 202-206.
51. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009; 118: 469-474.
52. Hayashi K, Ohara N, Jeon HJ, Akagi S, Takahashi K, Akagi T, Namba S. Gliosarcoma with features of chondroblastic osteosarcoma. Cancer 1993; 72: 850-855.
53. He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P, Capelle L, Delattre JY, Poirier J, Hoang-Xuan K. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 2001; 60: 863-871.
54. Heesters MA, Koudstaal J, Go KG, Molenaar WM. Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neurooncol 1999; 44: 255-266.
55. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
56. Hegi ME, Janzer R-C, Lambiv WL, Gorlia T, Kouwenhoven MCM, Hartmann C, Deimling von A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, Weller M, van den Bent MJ, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, and National Cancer Institute of Canada Clinical Trials Group. Presence of an oligoden-droglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC-26981/NCIC-CE.3 trial. Acta Neuropathol 2010; 123: 841-852.
57. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nistér M. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992; 52: 3213-3219.
58. Hoshino T, Wilson BC, Ellis WG. Gemistocytic astrocytes in gliomas. An autoradiographic study. J Neuropathol Exp Neurol 1975; 34: 263-281.
59. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010; 10: 319-331.
60. Ishizawa K, Kan-nuki S, Kumagai H, Komori T, Hirose T. Lipomatous primitive neuroectodermal tumor with a glioblastoma component: a case report. Acta Neuropathol 2002; 103: 193-198.
61. Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 2010; 9: 717-726.
62. Johnson MW, Lin D, Smir BN, Burger PC. Lipoglioblastoma: a lipidized glioma radiologically and histologically mimicking adipose tissue. World Neurosurg 2010; 73: 108-111.
63. Jones H, Steart PV, Weller RO. Spindle-cell glioblastoma or glio sarcoma? Neuropathol Appl Neurobiol 1991; 17: 177-187.
64. Joo M, Park S-H, Chang SH, Kim H, Choi C-Y, Lee C-H, Lee BH, Hwang YJ. Cytogenetic and molecular genetic study on glioblastoma arising in granular cell astrocytoma: a case report. Hum Pathol 2011; doi: 10.1016/j.humpath.2011.08.015 [Epub ahead of print].
65. Jung V, Romeike BF, Henn W, Feiden W, Moringlane JR, Zang KD, Urbschat S. Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. J Neuropathol Exp Neurol 1999; 58: 993-999.
66. Kandemir NO, Bahadir B, Gul S, Karadayi N, Ozdamar SO. Glio blastoma with primitive neuroectodermal tumor-like features: case report. Turk Neurosurg 2009; 19: 260-264.
67. Kaneshiro D, Kobayashi T, Chao ST, Suh J, Prayson RA. Chromosome 1p and 19q deletions in glioblastoma multiforme. Appl Immunohistochem Mol Morphol 2009; 17: 512-516.
68. Karina A, Jonker BP, Morey A, Selinger C, Gupta R, Buckland ME. Glioblastoma with primitive neuroectodermal tumour-like components. Pathology 2012; 44: 270-273.
69. Karremann M, Butenhoff S, Rausche U, Pietsch T, Wolff JEA, Kramm CM. Pediatric giant cell glioblastoma: New insights into a rare tumor entity. Neurooncol 2009; 11: 323-329.
70. Karremann M, Rausche U, Fleischhack G, Nathrath M, Pietsch T, Kramm CM, Wolff JEA. Clinical and epidemiological characteristics of pediatric gliosarcomas. J Neurooncol 2010; 97: 257-265.
71. Karsy M, Albert L, Tobias ME, Murali R, Jhanwar-Uniyal M. All-trans retinoic acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent manner. Anticancer Res 2010; 30: 4915-4920.
72. Karsy M, Arslan E, Moy F. Current Progress on Understanding Micro RNAs in Glioblastoma Multiforme. Genes Cancer 2012; 3: 3-15.
73. Kepes JJ, Fulling KH, Garcia JH. The clinical significance of "adenoid" formations of neoplastic astrocytes, imitating metastatic carcinoma, in gliosarcomas. A review of five cases. Clin Neuropathol 1982; 1: 139-150.
74. Kernohan JW, Mabon R F. A simplified classification of the gliomas. Proc Staff Meet Mayo Clin 1949; 24: 71-75.
75. Khanna M, Siraj F, Chopra P, Bhalla S, Roy S. Gliosarcoma with prominent smooth muscle component (gliomyosarcoma): a report of 10 cases. Indian J Pathol Microbiol 2011; 54: 51-54.
76. Kim Y, Suh Y-L, Sung C, Hong SC. Gliofibroma: a case report and review of the literature. J Korean Med Sci 2003; 18: 625-629.
77. Klink B, Schlingelhof B, Klink M, Stout-Weider K, Patt S, Schrock E. Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification. Cell Oncol (Dordr) 2011; 34: 261-275.
78. Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, Okamura A, Takakura N, Suda T, Ushio Y. Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 2001; 61: 6248-6254.
79. Kozak KR, Moody JS. Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro-oncology 2009; 11: 833-841.
80. Kösel S, Scheithauer BW, Graeber MB. Genotype-phenotype correlation in gemistocytic astrocytomas. Neurosurgery 2001; 48: 187-93; discussion 193-4.
81. Kraus JA, Felsberg J, Tonn JC, Reifenberger G, Pietsch T. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol Appl Neurobiol 2002; 28: 325-333.
82. Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Reifenberger G, Schlegel U. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol 2001; 101: 311-320.
83. Kros JM, Schouten WC, Janssen PJ, van der Kwast TH. Proliferation of gemistocytic cells and glial fibrillary acidic protein (GFAP)positive oligodendroglial cells in gliomas: a MIB-1/GFAP double labeling study. Acta Neuropathol 1996; 91: 99-103.
84. Kros JM, Waarsenburg N, Hayes DP, Hop WC, van Dekken H. Cytogenetic analysis of gemistocytic cells in gliomas. J Neuropathol Exp Neurol 2000; 59: 679-686.
85. Krouwer HG, Davis RL, Silver P, Prados M. Gemistocytic astrocytomas: a reappraisal. J Neurosurg 1991; 74: 399-406.
86. Larysz D, Kula D, Kowal M, Rudnik A, Jarza̧b M, Blamek S, Bie rzyńska-Macyszyn G, Kowalska M, Bażowski P, Jarza̧b B. Epidermal growth factor receptor gene expression in high grade gliomas. Folia Neuropathol 2011; 49: 28-38.
87. Lee D, Kang SY, Suh Y-L, Jeong JY, Lee J-I, Nam D-H. Clinicopatho-logic and genomic features of gliosarcomas. J Neurooncol 2012; 107: 643-650.
88. Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, Anastasiadis PZ. Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS ONE 2010; 5: e13665.
89. Louis DN, Ohgaki HH, Wiestler OD, Cavenee WK. Astrocytic tumors. In: WHO Classification of Tumours of the Central Nervous System. Louis DN, Ohgaki HH, Wiestler OD, Cavenee WK (ed.). WHO Press, Albany 2007.
90. Lusis EA, Travers S, Jost SC, Perry A. Glioblastomas with giant cell and sarcomatous features in patients with Turcot syndrome type 1: a clinicopathological study of 3 cases. Neurosurgery 2010; 67: 811-817; discussion 817.
91. MacDonald TJ, Aguilera D, Kramm CM. Treatment of high-grade glioma in children and adolescents. Neurooncology 2011; 13: 1049-1058.
92. Markesbery WR, Duffy PE, Cowen D. Granular cell tumors of the central nervous system. J Neuropathol Exp Neurol 1973; 32: 92-109.
93. Martinez R, Roggendorf W, Baretton G, Klein R, Toedt G, Lichter P, Schackert G, Joos S. Cytogenetic and molecular genetic analyses of giant cell glioblastoma multiforme reveal distinct profiles in giant cell and non-giant cell subpopulations. Cancer Genet Cytogenet 2007; 175: 26-34.
94. Martins DC, Malheiros SM, Santiago LH, Stávale JN. Gemistocytes in astrocytomas: are they a significant prognostic factor? J Neurooncol 2006; 80: 49-55.
95. Marucci G. The effect of WHO reclassification of necrotic anaplastic oligoastrocytomas on incidence and survival in glioblastoma. J Neurooncol 2011; 104: 621-622.
96. McNab AA, Daniel SE. Granular cell tumours of the orbit. Aust N Z J Ophthalmol 1991; 19: 21-27.
97. Meis JM, Ho KL, Nelson JS. Gliosarcoma: a histologic and immunohistochemical reaffirmation. Mod Pathol 1990; 3: 19-24.
98. Melaragno MJ, Prayson RA, Murphy MA, Hassenbusch SJ, Estes ML. Anaplastic astrocytoma with granular cell differentiation: case report and review of the literature. Human Pathology 1993; 24: 805-808.
99. Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, Coulibaly B, Fina F, Loundou A, Barrie M, Chinot O, Ouafik L, Figarella-Branger D. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radio-chemotherapy: a prospective patient cohort at a single institution. Ann Surg Oncol 2011; 18: 2937-2945.
100. Meyer-Puttlitz B, Hayashi Y, Waha A, Rollbrocker B, Boström J, Wiestler OD, Louis DN, Reifenberger G, Deimling von A. Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 1997; 151: 853-857.
101. Miller CR, Perry A. Glioblastoma. Arch Pathol Lab Med 2007; 131: 397-406.
102. Morantz RA, Feigin I, Ransohoff J. Clinical and pathological study of 24 cases of gliosarcoma. J Neurosurg 1976; 45: 398-408.
103. Motomura K, Natsume A, Watanabe R, Ito I, Kato Y, Momota H, Nishikawa R, Mishima K, Nakasu Y, Abe T, Namba H, Nakazato Y, Tashiro H, Takeuchi I, Mori T, Wakabayashi T. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Science 2012.
104. Mueller W, Lass U, Herms J, Kuchelmeister K, Bergmann M, Deimling von A. Clonal analysis in glioblastoma with epithelial differentiation. Brain Pathol 2001; 11: 39-43.
105. Müller W, Slowik F, Firsching R, Afra D, Sanker P. Contribution to the problem of giant cell astrocytomas. Neurosurg Rev 1987; 10: 213-219.
106. Mřrk SJ, Rubinstein LJ, Kepes JJ, Perentes E, Uphoff D F. Patterns of epithelial metaplasia in malignant gliomas. II. Squamous differentiation of epithelial-like formations in gliosarcomas and glioblastomas. J Neuropathol Exp Neurol 1988; 47: 101-118.
107. Nagaishi M, Kim Y-H, Mittelbronn M, Giangaspero F, Paulus W, Brokinkel B, Vital A, Tanaka Y, Nakazato Y, Legras-Lachuer C, Lachuer J, Ohgaki H. Amplification of the STOML3, FREM2, and LHFP Genes Is Associated with Mesenchymal Differentiation in Gliosarcoma. Am J Pathol 2012; 180: 1816-1823.
108. Nagaishi M, Paulus W, Brokinkel B, Vital A, Tanaka Y, Nakazato Y, Giangaspero F, Ohgaki H. Transcriptional Factors for Epithelial-Mesenchymal Transition Are Associated with Mesenchymal Differentiation in Gliosarcoma. Brain Pathol 2012; 22: 670-676.
109. Nagasaka T, Gunji M, Hosokai N, Hayashi K, Ikeda H, Ito M, Inao S. FISH 1p/19q deletion/imbalance for molecular subclassification of glioblastoma. Brain Tumor Pathol 2007; 24: 1-5.
110. Nakamura H, Makino K, Kuratsu J-I. Molecular and clinical ana-lysis of glioblastoma with an oligodendroglial component (GBMO). Brain Tumor Pathol 2011; 28: 185-190.
111. Neelima R, Gopalakrishnan CV, Thomas B, Radhakrishnan VV. Glioblastoma multiforme with epithelial differentiation. Neurol India 2011; 59: 918-920.
112. Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee WK, Matsutani M. Immunohistochemical analysis of the mutant epidermal growth factor, delta EGFR, in glioblastoma. Brain Tumor Pathol 2004; 21: 53-56.
113. Oh D, Prayson RA. Evaluation of epithelial and keratin markers in glioblastoma multiforme: an immunohistochemical study. Arch Pathol Lab Med 1999; 123: 917-920.
114. Ohgaki H, Kleihues P. Genetic profile of astrocytic and oligo-dendroglial gliomas. Brain Tumor Pathol 2011; 28: 177-183.
115. Ozolek JA, Finkelstein SD, Couce ME. Gliosarcoma with epithelial differentiation: immunohistochemical and molecular characterization. A case report and review of the literature. Modern Pathology 2004; 17: 739-745.
116. Palma L, Celli P, Maleci A, Di Lorenzo N, Cantore G. Malignant monstrocellular brain tumours. A study of 42 surgically treated cases. Acta Neurochir (Wien) 1989; 97: 17-25.
117. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
118. Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS, Onar-Thomas A, Baker JN, Gajjar A, Ellison DW, Baker SJ. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 2011; 29: 3999-4006.
119. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, Bax DA, Coyle B, Barrow J, Hargrave D, Lowe J, Gajjar A, Zhao W, Broniscer A, Ellison DW, Grundy RG, Baker SJ. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010; 28: 3061-3068.
120. Peraud A, Watanabe K, Plate KH, Yonekawa Y, Kleihues P, Ohgaki H. p53 mutations versus EGF receptor expression in giant cell glioblastomas. J Neuropathol Exp Neurol 1997; 56: 1236-1241.
121. Peraud A, Watanabe K, Schwechheimer K, Yonekawa Y, Kleihues P, Ohgaki H. Genetic profile of the giant cell glioblastoma. Lab Invest 1999; 79: 123-129.
122. Perry A, Aldape KD, George DH, Burger PC. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 2004; 101: 2318-2326.
123. Perry A, Miller CR, Gujrati M, Scheithauer BW, Zambrano SC, Jost SC, Raghavan R, Qian J, Cochran EJ, Huse JT, Holland EC, Burger PC, Rosenblumb MK. Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol 2009; 19: 81-90.
124. Perry JR, Ang LC, Bilbao JM, Muller PJ. Clinicopathologic features of primary and postirradiation cerebral gliosarcoma. Cancer 1995; 75: 2910-2918.
125. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173.
126. Pinto LW, Araújo MBM, Vettore AL, Wernersbach L, Leite ACC, Chimelli LMC, Soares FA. Glioblastomas: correlation between oligo-dendroglial components, genetic abnormalities, and prognosis. Virchows Arch 2008; 452: 481-490.
127. Pińa-Oviedo S, De León-Bojorge B, Cuesta-Mejías T, White MK, Ortiz-Hidalgo C, Khalili K, Del Valle L. Glioblastoma multiforme with small cell neuronal-like component: association with hu man neu-rotropic JC virus. Acta Neuropathol 2006; 111: 388-396.
128. Plessis du DG, Rutherfoord GS, Joyce KA, Walker C. Phenotypic and genotypic characterization of glioblastoma multiforme with epithelial differentiation and adenoid formations. Clin Neuropathol 2004; 23: 141-148.
129. Pollack I F. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. J Neurosurg Pediatr 2011; 8: 135-148.
130. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Boyett JM, Finlay JL, Sposto R, and Children's Cancer Group. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002; 346: 420-427.
131. Pollack IF, Hamilton RL, Burger PC, Brat DJ, Rosenblum MK, Murdoch GH, Nikiforova MN, Holmes EJ, Zhou T, Cohen KJ, Jakacki RI, Children's Oncology Group. Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. J Neu-rooncol 2010; 99: 155-163.
132. Pollack IF, Hamilton RL, James CD, Finkelstein SD, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL, Children's Oncology Group. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg 2006; 105: 418-424.
133. Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL. 06-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 2006; 24: 3431-3437.
134. Prayson RA. Lipomatous supratentorial primitive neuroectodermal tumor with glioblastomatous differentiation. Ann Diagn Pathol 2009; 13: 36-40.
135. Qaddoumi I, Sultan I, Gajjar A. Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer 2009; 115: 5761-5770.
136. Quezado M, Ronchetti R, Rapkiewicz A, Santi M, Blumenthal DT, Rushing EJ. Chromogenic in situ hybridization accurately identifies EGFR amplification in small cell glioblastoma multiforme, a common subtype of primary GBM. Clin Neuropathol 2005; 24: 163-169.
137. Quon H, Abdulkarim B. Adjuvant treatment of anaplastic oligo-dendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev 2008; (2): CD007104.
138. Reis RM, Hara A, Kleihues P, Ohgaki H. Genetic evidence of the neoplastic nature of gemistocytes in astrocytomas. Acta Neuropathol 2001; 102: 422-425.
139. Reis RM, Könü-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. Am J Pathol 2000; 156: 425-432.
140. Reis RM, Martins A, Ribeiro SA, Basto D, Longatto-Filho A, Schmitt FC, Lopes JM. Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas. Cell Oncol 2005; 27: 319-326.
141. Rickert CH, Paulus W. Genetic characterisation of granular cell tumours. Acta Neuropathol 2002; 103: 309-312.
142. Ringertz N. Grading of gliomas. Acta Pathol Microbiol Scand 1950; 27: 51-64.
143. Rodriguez FJ, Scheithauer BW, Giannini C, Bryant SC, Jenkins RB. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer 2008; 113: 2779-2789.
144. Rutka JT, Giblin JR, Hřifřdt HK, Dougherty DV, Bell CW, McCulloch JR, Davis RL, Wilson CB, Rosenblum ML. Establishment and characterization of a cell line from a human gliosarcoma. Cancer Research 1986; 46: 5893-5902.
145. Saad A, Mo J, Miles L, Witte D. Granular cell astrocytoma of the cerebellum: report of the first case. Am J Clin Pathol 2006; 126: 602-607.
146. Salvati M, Formichella AI, D'Elia A, Brogna C, Frati A, Giangaspero F, Delfini R, Santoro A. Cerebral glioblastoma with oligoden-drogliomal component: analysis of 36 cases. J Neurooncol 2009; 94: 129-134.
147. Sanders RP, Kocak M, Burger PC, Merchant TE, Gajjar A, Broniscer A. High-grade astrocytoma in very young children. Pediatr Blood Cancer 2007; 49: 888-893.
148. Sarkar C, Sharma MC, Sudha K, Gaikwad S, Varma A. A clinico-pathological study of 29 cases of gliosarcoma with special reference to two unique variants. Indian J Med Res 1997; 106: 229-235.
149. Schiffman JD, Hodgson JG, Vandenberg SR, Flaherty P, Polley M-YC, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010; 70: 512-519.
150. Schittenhelm J, Psaras T. Glioblastoma with granular cell astro-cytoma features: a case report and literature review. Clin Neuropathol 2010; 29: 323-329.
151. Schlegel J, Piontek G, Kersting M, Schuermann M, Kappler R, Scherthan H, Weghorst C, Buzard G, Mennel H. The p16/Cdkn2a/ Ink4a gene is frequently deleted in nitrosourea-induced rat glial tumors. Pathobiology 1999; 67: 202-206.
152. Schwartzentruber J, Korshunov A, Liu X-Y, Jones DTW, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann
153. Seker A, Ozek MM. Congenital glioblastoma multiforme. Case report and review of the literature. J Neurosurg 2006; 105: 473-479.
154. Shapiro JR, Yung WK, Shapiro WR. Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res 1981; 41: 2349-2359.
155. Shi Y, Morgenstern N. Granular cell astrocytoma. Arch Pathol Lab Med 2008; 132: 1946-1950.
156. Shinojima N, Kochi M, Hamada J-I, Nakamura H, Yano S, Makino K, Tsuiki H, Tada K, Kuratsu J, Ishimaru Y, Ushio Y. The influence of sex and the presence of giant cells on postoperative longterm survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg 2004; 101: 219-226.
157. Sibenaller ZA, Etame AB, Ali MM, Barua M, Braun TA, Casavant TL, Ryken TC. Genetic characterization of commonly used glioma cell lines in the rat animal model system. Neurosurg Focus 2005; 19: E1.
158. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG, Aldape K. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001; 61: 1122-1128.
159. Singh AD, Iftinca M, Easaw JC. Lipidized glioblastoma: Pathological and molecular characteristics. Neuropathology 2012.
160. Smith SF, Simpson JM, Brewer JA, Sekhon LHS, Biggs MT, Cook RJ, Little NS. The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients. J Neurooncol 2006; 80: 75-82.
161. Song X, Andrew Allen R, Terence Dunn S, Fung K-M, Farmer P, Gandhi S, Ranjan T, Demopoulos A, Symons M, Schulder M, Li JY. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Int J Clin Exp Pathol 2011; 4: 651-660.
162. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairn-cross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, and National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
163. Takeuchi H, Hosoda T, Kitai R, Kodera T, Arishima H, Tsunetoshi K, Neishi H, Yamauchi T, Sato K, Imamura Y, Itoh H, Kubota T, Ki kuta K. Glioblastoma with oligodendroglial components: glioblastoma or anaplastic oligodendroglial tumors. Brain Tumor Pathol 2012; 29: 154-159.
164. Tihan T, Vohra P, Berger MS, Keles GE. Definition and diagnostic implications of gemistocytic astrocytomas: a pathological perspective. J Neurooncol 2006; 76: 175-183.
165. Varlet P, Soni D, Miquel C, Roux F-X, Meder J-F, Chneiweiss H, Daumas-Duport C. New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases. Neurosurgery 2004; 55: 1377-1391, discussion 1391-1392.
166. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
167. Vordermark D, Ruprecht K, Rieckmann P, Roggendorf W, Vin ce GH, Warmuth-Metz M, Kölbl O, Flentje M. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC Cancer 2006; 6: 247.
168. Wang Y, Li S, Chen L, You G, Bao Z, Yan W, Shi Z, Chen Y, Yao K, Zhang W, Kang C, Jiang T. Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neurooncology 2012; 14: 518-525.
169. Watanabe K, Peraud A, Gratas C, Wakai S, Kleihues P, Ohgaki H. p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol 1998; 95: 559-564.
170. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H. Role of gemistocytes in astrocytoma progression. Lab Invest 1997; 76: 277-284.
171. Wikstrand CJ, Bigner SH, Bigner DD. Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. Cancer Res 1983; 43: 3327-3334.
172. Wolańczyk M, Hułas-Bigoszewska K, Witusik-Perkowska M, Papierz W, Jaskólski D, Liberski PP, Rieske P. Imperfect oligoden-drocytic and neuronal differentiation of glioblastoma cells. Folia Neuropathol 2010; 48: 27-34.
173. Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, Bouffet E, Hawkins C. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 2010; 28: 1337-1344.